Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
integralmolecular.com

See what CB Insights has to offer

Founded Year

2001

Stage

Loan | Alive

Total Raised

$1.18M

Last Raised

$680K | 2 yrs ago

About Integral Molecular

Integral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.

Integral Molecular Headquarter Location

3711 Market Street Suite 900

Philadelphia, Pennsylvania, 19104,

United States

215-966-6061

Latest Integral Molecular News

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

Nov 3, 2021

11/03/2021 | 08:01am EDT Message : *Required fields PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for multiple cancers. Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities. "This agreement with Integral Molecular will allow AstraZeneca to generate additional novel cancer therapies and advance our goal of delivering personalised treatments to improve patient outcomes," said Mark Cobbold, VP, Discovery, Oncology R&D at AstraZeneca. "These antibodies can be incorporated into a number of therapeutic modalities and align with AstraZeneca's ongoing pursuit of high-quality innovation to deliver life-changing treatments that increase the potential for cure." "Specificity is incredibly important for therapies designed to eliminate cancer cells, since mistargeting can have serious safety ramifications for patients," said Benjamin Doranz, CEO and co-founder of Integral Molecular. "Our program has produced antibodies with picomolar affinity and high specificity even against conserved targets that have proven difficult to generate antibodies against. The specificity of these antibodies is a testament to the dedication and efforts of our talented team." The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular's platforms designed to yield antibodies against structurally complex membrane proteins. Together, the MPS Antibody Discovery platform , Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity. About Integral Molecular Integral Molecular ( integralmolecular.com ) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses. Press Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Integral Molecular

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Integral Molecular is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Integral Molecular Patents

Integral Molecular has filed 8 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Animal viral diseases
  • Biological weapons
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/27/2017

10/5/2021

Hemorrhagic fevers, Zoonoses, Biological weapons, Ebola, Animal viral diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/27/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/5/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Hemorrhagic fevers, Zoonoses, Biological weapons, Ebola, Animal viral diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Integral Molecular Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Integral Molecular Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.